23rd JSSX Annual Meeting jssxlogo
Japanese  

Symposium etc.

Update: 08/10/09

Symposium

Symposium 1 (S1)

[The bench-to-bedside researches for renal drug transporters and channels]

  Organizer：  
  Mikihisa Takano (Department of Pharmaceutics and Therapeutics, Graduate School of Biomedical Sciences, Hiroshima University)
  Hideyuki Saito (Department of Pharmacy, Kumamoto University Hospital)
     

【Plenary Lecture】
New progress in transporter and channel research
   Sei Sasaki
(Department of Nephrology, Tokyo Medical and Dental University)

  1. Proximal tubule-specific transporter manipulation in transgenic animals
       Takaaki Abe
    (Division of Nephrology, Endocrinology, and Vascular Medicine, Department of Medicine, Tohoku University Graduate School of Medicine）
  2. Renal urate transpoters and serum urate disorder
       Naohiko Anzai1), Hitoshi Endou1,2)
    (1)Department of Pharmacology and Toxicology, Kyorin University School of Medicine, 2) J-Pharma Co. Ltd）
  3. Mchanisms of tubular secretion of drugs in the kidney, and drug interactions involving drug transporters
       Hiroyuki Kusuhara
    (Graduate School of Pharmaceutical Sciences, The University of Tokyo)
  4. Pathophysiological roles of renal drug transpoters
       Satohiro Masuda, Ken-ichi Inui
    (Department of Pharmacy, Kyoto University Hospital)

Symposium 2 (S2)

[Recent progress in regulation mechanisms of drug metabolizing enzymes and transporters]

  Organizer:  
  Tsuyoshi Yokoi (Drug Metabolism and Taxicology, Graduate School of Medical Sciences,Kanazawa University)
  Tomohiro Terada (Department of Pharmacy, Kyoto University Hospital)
     

Overview
Tsuyoshi Yokoi
(Drug Metabolism and Taxicology, Graduate School of Medical Sciences,Kanazawa University)

  1. Bile acid, lipid and fxr control
       Masaaki Miyata, Yuki Takamatsu, Masahiro Nomoto, Yasushi Yamazoe
    (Division of Drug Metabolism and Molecular Toxicology, Graduate School of Pharmaceutical Sciences, Tohoku University)
  2. Differentiation of human embryonic stem cells into hepatocytes and pharmacokinetic studies
       Tamihide Matsunaga, Shigeru Ohmori
    (Department of Pharmacy, Shinshu University Hospital)
  3. Regulation of drug metabolizing enzymes and nuclear receptors by micrornas
       Miki Nakajima, Shingo Takagi, Sayaka Komagata, Takuya Mohri, Yuki Tsuchiya, and Tsuyoshi Yokoi.
    (Drug Metabolism and Taxicology, Graduate School of Medical Sciences,Kanazawa University)
  4. Molecular clock mechanisms of drug pharmacokinetics
       Naoya Matsunaga, Satoru Koyanagi, Shigehiro Ohdo
    (Pharmaceutics, Faculty of Pharmaceutical Sciences, Kyushu University)
  5. Gene regulation of drug transpoters
       Tomohiro Terada, Ken-ichi Inui
    (Department of Pharmacy, Kyoto University Hospital)

Symposium 3 (S3)

“International symposium on development of albumins with new functions and clinical applications”
Organizer:
   Masaki Otagiri (Japan)
   U. Kragh-Hansen (Denmark)

【Welcoming Speech】 Masaki Otagiri (Japan)

Session 1: Current approaches in protein binding studies

  1. Crystallographic analysis of small molecule binding to HSA: what have we learned?
       Stephen Curry (United Kingdom)
  2. Site-directed mutagenesis study of key amino acids in the ligand binding domains of human serum albumin
       Chung-Eun Ha (USA)
  3. Identification of drug binding site on plasma proteins using photoaffinity labelling technique
       Victor Tuan Giam Chuang (Australia)

Session 2: Biological activities for new therapeutic opportunities

  1. Role of albumin in amyloidosis: a novel therapeutic target in amyloid formation
       Yukio Ando (Japan)
  2. The MHC class I-related FcRn protects albumin and IgG from degradation: implications for development and evaluation of new diagnostics and therapeutics
       Jan Terje Andersen (Norway)

Session 3: Biomarkers of Diseases

  1. Hotspots sites for glycation of human serum albumin and effect on functional activity and degradation
       Paul J. Thornalley (United Kingdom)
  2. Ischemia modified albumin
       David C. Gaze (United Kingdom)

Session 4: Albumin functionalization and clinical applications

  1. NO-induced protein Cys modification and its potential clinical application
       Takaaki Akaike (Japan)
  2. Albumin-heme complexes: heme pocket architecture for modulation of oxygen-binding property
       Teruyuki Komatsu (Japan)
  3. Albumin dialysis for extracorporeal liver support: basics and clinical results
       Steffen Mitzner (Germany)

【Distinguished Lecture】
Albumin as fatty acid transporter
   Ger J van der Vusse (The Netherland)

【Closing Speech】 Ulrich Kragh-Hansen (Denmark)

Symposium 4 (S4)

[Asia Pacific regional ISSX-JSSX joint symposium]
“Pharmacogenomics in Asia - the present & the future; how to translate genomic informations into clinical therapeutics and drug development”
Organizer:
   Ichiro Ieiri (Japan)
   Jin-ding Huang (Taiwan)

Introduction
Ichiro Ieiri (Kyushu University, Japan)

  1. Pharmacogenomics research and translation of the genomic information into clinical therapeutics in korea
      In-Jin Jang (Seoul National University College of Medicine, Korea)
  2. Pharmacogenomics-guided strategy for eradication of h. Pylori
      Takahisa Furuta (Hamamatsu University School Of Medicine, Japan)
  3. Transcriptional inhibition and the relevance with drug development
      Jin-ding Huang (National Cheng Kung University, Taiwan)
  4. Current status and future perspective in pharmacogenomic biomarkers in clinical trials
      Yasuhiko Imai (JPMA, Japan)
  5. Regulatory issues in pharmacogenomics for new drug developments
      Yoshiaki Uyama (Pharmaceuticals & Medical Devices Agency, Japan)
  6. Ethnic difference of drug disposition: contributing factors and perspectives
      Jae-gook Shin (Inje University College Of Medicine, Korea)

Closing remarks
Jin-ding Huang (National Cheng Kung University, Taiwan)

Symposium 5 (S5)

"Clinical pharmacokinetics and pharmacology of anticancer agents: towards the personalized medicine"
Organizers：
  Yusuke Tanigawara (Keio University)
  Jiichiro Sasaki（Kumamoto University Hospital）

  1. Ugt1a1/abcc2 and pharmacokinetics of irinotecan hydrochloride
      Ken-ichi Fujita (Saitama International Medical Center-Comprehensive Cancer Center, Saitama Medical University)
  2. Impact of cytidine deaminase (Cda)-related biomarkers on clinical outcomes of gemcitabine-based chemotherapies
      Nahoko Kaniwa1) and Hideki Ueno2) (1)National Institute of Health Sciences, 2)National Cancer Center Hospital)
  3. Pharmacogenomics of molecular targeted trags in cancer treatments
      Kenji Tamura (National Cancer Center Hospital)
  4. Metabolomic and proteomic analyses for pharmacological responses to anticancer agents
      Yusuke Tanigawara, Akito Nishimuta, Sayo Suzuki, Eri Arita, Mitsuhiro Watanabe (Department of Pharmacy, School of Medicine, Keio University)

General discussion
Yusuke Tanigawara (Keio University)
Jiichiro Sasaki（Kumamoto University Hospital）

Forum 2008

  Perspective on clinical drug-interactions in the 21st century　- preclinical, clinical and regulatory aspects –
  Program Chairman: Shizuo Narimatsu
（Okayama University Graduate School of Biomedical Sciences)

Opening remarks
Shizuo Narimatsu (Okayama University)

  1. Clinical importance of drug interactions
      Sumio Hirata　(Kumamoto University)
  2. Pharmacokinetic studies of drug interaction caused by p-glycoprotein in healthy subjects
    −Comparison with those caused by CYP3A−
      Tomonori Tateishi　(Hirosaki University)
  3. Current situation of the clinical drug interaction studies in the drug development process
      Toshiko Koue　(Otsuka Pharmaceutical Co., Ltd)
  4. Role of drug-drug interaction studies in safety assessment of drugs
      Masahiro Tohkin　 (National Institute of Health Sciences)
  5. Construction and evaluation of CYP3A-HAC mice with the human CYP3A cluster for drug-drug interaction study
      Kaoru Kobayashi1, Kan Chiba1, Kazuma Tomizuka2, Yasuhiro Kazuki3 and Mitsuo Oshimura3,4
    (1Chiba University, 2KIRIN Pharma Co. Ltd., 3Tottori University and 4Chromocenter Inc.)
  6. Personalized therapy and drug-drug interaction
      Akihiro Hisaka　(University of Tokyo Hospital)
  7. For the substantial interaction of in vitro data of drug-drug interaction
      Yasushi Yamazoe　(Tohoku University)

General discussion
Shizuo Narimatsu (Okayama University)
Shinsaku Naito (Otsuka Pharmaceutical Factory Inc.)
Hideyuki Yamada (Kyushu University)

Young Scientists' Symposium

  Future perspectives of drug discovery based on exploratory and innovative technologies
  Program Chairman: Katsuhisa Inoue
（Nagoya City University　Graduate School of Pharmaceutial Sciences)
  1. RNA technology through design and evolution
      Yoshiya Ikawa(Kyushu University)
  2. Biomolecular imaging based on protein reconstitution methods
      Takeaki Ozawa(the University of Tokyo)
  3. QT prolongation assay using beating cardiomyocyte derived from primate ES cell
      Yasuyuki Asai(ReproCELL Incorporated)
  4. HGF as an innovative drug for vascular regeneration
      Hironori Nakagami(Osaka University)
  5. Theranostic application of telomerase-specific oncolytic viruses for human cancer
      Toshiyoshi Fujiwara(Okayama University)

※Please acknowledge that this program is the one as of September, 2008, and some changes will be expected in the future beforehand.

 
(C) 2008 JSSX